Latest News

FDA approves first drug for treatment of adult AML patients with specific genetic mutation




The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation.

Source link




Related posts

Phase 1 study shows novel KRAS inhibitor well tolerated by patients with adenocarcinoma and non-small cell lung cancer

Newsemia

With European backing, the world is on the brink of the first approved Ebola vaccine

Newsemia

How To Run Properly And Achieve Fitness

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy